More recent work suggests that, as with other cancers, de novo glutamine metabolism serves as a nitrogen donor for biosynthetic purposes through the activity of GS and is necessary to drive OvCa growth: specifically, targeting stromal GS activity and GLS activity in ovarian cancer cells reduced tumor growth and metastasis [92]. The gene discussed is GLUL; the disease is ovarian cancer.